Cramer: The lucrative journey of Allergan
November 17, 2014 at 18:07 PM EST
Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.